Genentech's Enspryng approved by FDA as first at‑home subcutaneous IL‑6R therapy for thyroid eye disease
- Enspryng (satralizumab‑mwge) is the first at‑home subcutaneous treatment for TED and is administered by patient or caregiver with maintenance dosing every four weeks.
- In SatraGO‑2, proptosis response in active TED was 52.9% with Enspryng versus 23.4% with placebo.
- In SatraGO‑2, diplopia reduction in active TED was 60.7% with Enspryng versus 25.8% with placebo.
- The SatraGO program comprised two Phase III trials that enrolled 258 patients across 19 countries; SatraGO‑1 did not meet its pre‑specified primary endpoint at week 24.
Approval and administration
Genentech announced FDA approval of Enspryng (satralizumab‑mwge) for adults with thyroid eye disease (TED), establishing the first at‑home subcutaneous treatment option for the condition. Enspryng can be administered by a person living with TED or a trained caregiver, with maintenance dosing every four weeks.
Clinical evidence
The approval was supported by the Phase III SatraGO program (SatraGO‑1 and SatraGO‑2). While SatraGO‑1 did not meet its pre‑specified primary endpoint at week 24, SatraGO‑2 demonstrated significant, clinically meaningful benefits: a proptosis response of 52.9% with Enspryng versus 23.4% with placebo and diplopia reduction of 60.7% versus 25.8% in the active TED population. The two trials enrolled a total of 258 patients across 19 countries, and no new safety signals were identified.
Mechanism and prior approvals
Enspryng is a humanized monoclonal antibody that binds soluble and membrane‑bound interleukin‑6 receptors (IL‑6R) to inhibit IL‑6 signaling; it employs Chugai’s antibody recycling technology for pH‑dependent binding and extended target engagement. The product is already approved for neuromyelitis optica spectrum disorder (NMOSD) since 2020.
Safety and regulatory status
The safety profile in TED was consistent with prior NMOSD experience. The FDA accepted a priority review for an sBLA in myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD) in September 2026, with an action expected in January 2027. Genentech also provides patient‑support services to assist access and reimbursement for prescribed patients.
Source: Genentech